Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients

References

• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095–101.
   PubMed Web of Science ®Google Scholar
• Dasu A. Radiobiology of prostate cancer. In: Ponsky LE, Fuller DB, Meier RM, Ma C-MC, editors. Robotic radiosurgery. Treating prostate cancer and related genitourinary applications. Berlin: Springer; 2012. pp. 79–101.
   Google Scholar
• Dasu A. Is the α/β value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 2007;19:289–301.
   PubMed Web of Science ®Google Scholar
• Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021–31.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52:6–13.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56:1093–104.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Ritter MA. The α/β ratio for prostate cancer: What is it, really? Radiother Oncol 2005;76:1–3.
   PubMed Web of Science ®Google Scholar
• Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, . Use of individual fraction size data from 3756 patients to directly determine the α/β ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007;68:24–33.
   PubMed Web of Science ®Google Scholar
• Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, . Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics . Int J Radiat Oncol Biol Phys 2011;79:195–201.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82:e17–24.
   PubMedGoogle Scholar
• Lindsay PE, Moiseenko VV, Van Dyk J, Battista JJ. The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer. Phys Med Biol 2003;48:507–22.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 2001;92:1281–7.
   PubMed Web of Science ®Google Scholar
• Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS, . Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003;57:1254–9.
   Google Scholar
• Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, . Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005;92:488–98.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes . Int J Radiat Oncol Biol Phys 2005;63:1463–8.
   PubMed Web of Science ®Google Scholar
• Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, . Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132–8.
   PubMed Web of Science ®Google Scholar
• Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, . Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy . Radiother Oncol 2005;75:74–82.
   PubMed Web of Science ®Google Scholar
• Higgins GS, McLaren DB, Kerr GR, Elliott T, Howard GC. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:982–9.
   PubMedGoogle Scholar
• Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, . Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–6.
   PubMed Web of Science ®Google Scholar
• Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, . Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518–26.
   PubMed Web of Science ®Google Scholar
• Williams SG, Duchesne GM, Gogna NK, Millar JL, Pickles T, Pratt GR, . An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. Int J Radiat Oncol Biol Phys 2006;65:351–7.
   Google Scholar
• Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, . Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006;66:1072–83.
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, . Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475–87.
   PubMed Web of Science ®Google Scholar
• Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007;68:682–9.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007;68:1424–30.
   PubMed Web of Science ®Google Scholar
• Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, . Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330–7.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, . Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028–33.
   PubMed Web of Science ®Google Scholar
• Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol 2009;93:185–91.
   PubMed Web of Science ®Google Scholar
• Goldner G, Bombosch V, Geinitz H, Becker G, Wachter S, Glocker S, . Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. Strahlenther Onkol 2009;185: 94–100.
   Google Scholar
• Leborgne F, Fowler J. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: A nonrandomized contemporary comparison. Int J Radiat Oncol Biol Phys 2009;74:1441–6.
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, . A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11–8.
   PubMed Web of Science ®Google Scholar
• Buyyounouski MK, Price Jr. RA, Harris EE, Miller R, Tome W, Schefter T, . Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010;76: 1297–304.
   Google Scholar
• Rene N, Faria S, Cury F, David M, Duclos M, Shenouda G, . Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;77:805–10.
   Google Scholar
• Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, . Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011;117:1429–37.
   PubMed Web of Science ®Google Scholar
• Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, . 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056–63.
   PubMed Web of Science ®Google Scholar
• Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol 2011;6:3.
   PubMed Web of Science ®Google Scholar
• Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, . Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: Late toxicity. Int J Radiat Oncol Biol Phys 2012;82: 898–905.
   PubMed Web of Science ®Google Scholar
• Roach III M, Hanks G, Thames Jr. H, Schellhammer P, Shipley WU, Sokol GH, . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
   PubMed Web of Science ®Google Scholar
• Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982;8:1981–97.
   PubMed Web of Science ®Google Scholar
• Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679–94.
   PubMed Web of Science ®Google Scholar
• Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, . The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol2010;96:6–12.
   Google Scholar
• Dasu A, Toma-Dasu I, Fowler JF. Should single or distributed parameters be used to explain the steepness of tumour control probability curves? Phys Med Biol 2003;48:387–97.
   PubMed Web of Science ®Google Scholar
• Cosset JM. Hypofractionnement en radiothérapie: Le retour? Cancer Radiother 2005;9:366–73.
   Google Scholar
• D’Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, . Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284:1280–3.
   PubMed Web of Science ®Google Scholar
• Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:553–61.
   Google Scholar
• Diez P, Vogelius IS, Bentzen SM. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int J Radiat Oncol Biol Phys 2010;77:1066–71.
   PubMed Web of Science ®Google Scholar
• Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000;48:507–12.
   PubMed Web of Science ®Google Scholar
• Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, . Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:993–1002.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Gustafson GS, . An analysis of clinical and treatment related prognostic factors on outcome using biochemical control as an end-point in patients with prostate cancer treated with external beam irradiation. Radiother Oncol 1997;44:223–8.
   Google Scholar
• D’Ambrosio DJ, Li T, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does treatment duration affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys 2008;72:1402–7.
   PubMed Web of Science ®Google Scholar
• Toma-Dasu I, Dasu A, Brahme A. Dose prescription and optimisation based on tumour hypoxia. Acta Oncol 2009;48:1181–92.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: Tolerable levels in altered fractionation schedules. Radiother Oncol 2003;69:161–8.
   PubMed Web of Science ®Google Scholar